AllSight
Companies · LQDA · Pharmaceutical Preparations

Liquidia Corp (LQDA)

Liquidia Corp (LQDA) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Liquidia Corp (LQDA) stock — financials & valuation

Key numbers for Liquidia Corp (LQDA): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 70/100 — a percentile rank of Liquidia Corp’s fundamentals against Manufacturing peers, weakest on valuation. A quality ranking, not a price prediction.

Market cap$2.5B
P / E18.1×
P / S5.6×
EV / EBITDA14.1×
Gross margin92.5%
Operating margin37.4%
Net margin30.7%
Return on equity71.0%
ROIC179.6%
Revenue growth2233.6%
Debt / equity0.9×
Dividend yield0.0%

Is Liquidia Corp overvalued? P/S looks undervalued vs its 5-year range; P/B looks fair vs its 5-year range.

Independent of the events above — derived from Liquidia Corp’s own financial statements and shown as context, never as advice.

Sep 30, 2026Two claims upheld
Liquidia patent ruling upholds YUTREPIA infringement, putting PH-ILD access at risk
Sep 3, 2026Fast Track designation
Liquidia wins Fast Track for YUTREPIA Raynaud’s program, but efficacy remains untested
Aug 12, 2026Miss
Profitability surged—but the YUTREPIA ramp still came in just shy
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact